Navigation Links
Sysmex XE-2100™ Automated Hematology Analyzer

ProductsSysmex XE-2100™ Automated Hematology Analyzer
Company Sysmex America, Inc.
Item Sysmex XE-2100™ Automated Hematology Analyzer
Features Accuracy
  • Sensitive enough to detect as few as 0.1 NRBCs per 100 WBCs
  • Two state-of-the-art platelet methodologies, impedance and fluorescent optical, to assure accurate and reliable platelet counts without the need form manual confirmation procedures
  • HPC parameter offers a rapid, economical way to monitor patients on G-CSF therapy to determine the optimum time for harvesting stem cells for transplants

Reliability

  • Offers multiple discrete testing modes and real time random access analysis for testing flexibility and reagent savings
  • Remote diagnostics capability accelerates and simplifies service support
  • Throughput of up to 150 samples per hour for rapid test reporting

User-Friendly

  • Windows User Interface allows for easy operation
  • Customized screen layouts for maximum flexibility in information management
  • Network capabilities allow for easy integration into computer network system
  • Insight, our advanced web-based quality control program gives you QC results anytime, anywhere
Description The Sysmex XE-2100 provides users with the rapid, reliable test results that are essential for advanced patient diagnosis and therapeutic monitoring. With the power of fluorescent flow cytometry and advanced cell-counting methods, the XE-2100 offers a complete CBC with an extended differential that includes automatic enumeration of NRBC, HPC and IG. Fully automated reticulocytes and IRF results are available to aid the physician in monitoring erythropoietic activity. With a throughput of up to 150 samples per hour, the XE-2100 offers the speed and versatility for laboratories with all kinds of patient populations.
Info Sysmex America, Inc.Call Sysmex America, Inc. to buy products (US and Canada only; other locations use number below) USACanada1-866-394-3469

Customer Service: 1-800-379-7639
Web site: http://www.sysmex.com/

Related medicine products :

1. Sysmex UF-100 Fully Automated Urine Cell Analyzer
2. Sysmex UF-50™ Fully Automated Urine Cell Analyzer
3. Sysmex KX-21N Automated Hematology Analyzer
4. Sysmex CA-1500 Automated Coagulation Analyzer
5. Sysmex CA-500 Series Automated Coagulation Analyzer
6. Sysmex CA-7000 Automated Coagulation Analyzer
7. Dade DAC II Automated Cell Washer
8. Automated Blood Coagulation Analyzer
9. Microplate ELISA Washers - Automated Microplate Washer
10. ACS:180 SE Automated Chemiluminescence System
11. Semi-Automated Chemistry Analyzer
...ence laboratory and a worldwide leader in innovati...s an extensive test menu of highly complex and uni...gy. Owned by the University of Utah, ARUP Laborato...'s university teaching hospitals and children's ho...
...ence laboratory and a worldwide leader in innovati...s an extensive test menu of highly complex and uni...gy. Owned by the University of Utah, ARUP Laborato...'s university teaching hospitals and children's ho...
...ence laboratory and a worldwide leader in innovati...s an extensive test menu of highly complex and uni...gy. Owned by the University of Utah, ARUP Laborato...'s university teaching hospitals and children's ho...
...ence laboratory and a worldwide leader in innovati...s an extensive test menu of highly complex and uni...gy. Owned by the University of Utah, ARUP Laborato...'s university teaching hospitals and children's ho...
Medicine Products:
(Date:11/9/2009)... formation could boost self-esteem, researchers sa... Autistic children are more likely to have handwri...than those without autism, researchers say. , T...alf of the study participants had autism spectrum ...e normal range for perceptual reasoning on an IQ t...
(Date:11/9/2009)...v. 9 /PRNewswire-FirstCall/ - Hard To Treat Diseas...y that Novartis, a US$41 billion international hea..., H1N1 Vaccine partner, Zhejiang Tianyuan Bio-Phar... of Switzerland will begin a five-year, $1 billion...dramatically increase its investment in its China ...
(Date:11/9/2009)... New study highlights positive influence of sports... Rosemont, IL (Vocus) November 9, 2009 -- As...reases. Recent research has highlighted the import...revent these issues. However, a new study publishe...: A Multidisciplinary Approach reveals that there...
(Date:11/9/2009)...mes 2010 National Ambassador ,, WHITE PLAINS,...ffman of Weston, Fla., was born so early and with ...ot say whether he would survive -- or if he would ...d was named March of Dimes 2010 National Ambassado..."My first minutes of motherhood and I was complete...
(Date:11/9/2009)...people went from incapacitated to working again, ... Electrical stimulation of a certain area of the b...epression, say German researchers. , They impla...he brains of 10 people. This area of the brain is...e remember good experiences and puts them in a sta...
Breaking Medicine News(10 mins):Health News:Handwriting Skills May Lag in Kids With Autism 2Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 2Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 3Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 4Health News:High Impact Sports Participation May Improve Bone Mineral Density in Mature Athletes 2Health News:Six-Year-Old Survivor Fights for Preemies Like Himself 2Health News:Six-Year-Old Survivor Fights for Preemies Like Himself 3Health News:Brain Stimulation May Ease Treatment-Resistant Depression 2
...SSEN, Netherlands, May 7 Health ingredients Europ...food & beverage trade show, has been shortlist...est Trade Show Over 2000m2 Award, announced UBM In...ought together 7328 attendees with 450 exhibitors....
...e leader of dementia research in CSIRO,s Preventat...a Szoeke, says the report highlights the challenge...rs predicted to double to 465,000 by 2030. , "Abo...is crisis more effectively." , "By the time suffe...
...g Adults with AD/HD Make a Visit to the Halls of C...rce and Funding for the Mental Health Disorder , ...ll mark the fourth annual national Children,s Ment...ty Disorder (CHADD) and the American Academy of Ch...
...erence Call to Follow Release , , DENVER, May 7 ...the "Company") (OTC Bulletin Board: GLOB), an inte...y, will report its first quarter financial results... http://www.newscom.com/cgi-bin/prnh/20040226/GLO...
...ADELPHIA, May 7 Major League Baseball (MLB) has s...mask legal but banned substances for multi-million...estruction of the game as we know it. Sports team ...fine how the game should be run. , , "MLB is set ...
...ESTER, N.Y., May 7 Recent scientific studies publ...cinogenesis, Oncology, British Journal of Urology,... food extracts Quercetin, EGCG, Glycyrrhizin, and ...nding formulation. Gene-Eden was introduced in Feb...
Other Medicine News:Health News:Health ingredients Europe Shortlisted for AEO's Best Trade Show Over 2000m2 Award 2Health News:Dementia: Early detection is key 2Health News:The New Face of AD/HD Comes to Capitol Hill 2Health News:Global Med Technologies(R), Inc. to Report First Quarter Financial Results on Friday, May 15, 2009 2Health News:Global Med Technologies(R), Inc. to Report First Quarter Financial Results on Friday, May 15, 2009 3Health News:Is Bailout of Major League Baseball Next? Book Explains How Baseball Like Big Businesses Will Fail 2Health News:The Center for the Biology of Chronic Disease Highlights Anti-Cancer Activities of the Food Extracts Quercetin, EGCG, Glycyrrhizin, and Trans-Cinnamaldehyde 2
(Date:11/9/2009)...wire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Na... the third quarter ended September 30, 2009. ,,...on stockholders in the third quarter of 2009 of $3... loss allocable to common stockholders in the thir...hare, and a net loss allocable to common stockhold...
(Date:11/9/2009)...re/ -- Groundbreaking articles in current issues o...time explore, in depth, the emergence of cannabino...ers and its potential benefits for patients. ,,...gton authors, Sunil Aggarwal, PhD who is a member ...ram and who conducted the article,s research and G...
(Date:11/9/2009)...re/ -- Celling Technologies, a subsidiary of Spine...is, Inc. to research potential applications for ad... acquired the global rights in spine for Tissue Ge...nology in November of 2007. Replacing the prior a...lling Technologies to further research adipose tis...
Breaking Medicine Technology:Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 2Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 3Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 4Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 5Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 6Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 7Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 8Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 9Medicinal Use of Marijuana: Past, Present and Future...A Fresh Look by Experts in the Field 2Celling Technologies Signs Exclusive Agreement to Research and Develop Adipose Tissue Stem Cell Technology in Regenerative Medicine Institutes 2Celling Technologies Signs Exclusive Agreement to Research and Develop Adipose Tissue Stem Cell Technology in Regenerative Medicine Institutes 3HHS Awards MedImmune Contract to Manufacture Live Attenuated Nasal Spray Vaccine for Novel Influenza A 28H1N1 29 12381 1HHS Awards MedImmune Contract to Manufacture Live Attenuated Nasal Spray Vaccine for Novel Influenza A 28H1N1 29 12381 2HHS Awards MedImmune Contract to Manufacture Live Attenuated Nasal Spray Vaccine for Novel Influenza A 28H1N1 29 12381 3HHS Awards MedImmune Contract to Manufacture Live Attenuated Nasal Spray Vaccine for Novel Influenza A 28H1N1 29 12381 4Proteolix Presents Positive Clinical Data for Carfilzomib in Multiple Myeloma at the 2009 ASCO Annual Meeting 4502 1Proteolix Presents Positive Clinical Data for Carfilzomib in Multiple Myeloma at the 2009 ASCO Annual Meeting 4502 2Proteolix Presents Positive Clinical Data for Carfilzomib in Multiple Myeloma at the 2009 ASCO Annual Meeting 4502 3Proteolix Presents Positive Clinical Data for Carfilzomib in Multiple Myeloma at the 2009 ASCO Annual Meeting 4502 4Proteolix Presents Positive Clinical Data for Carfilzomib in Multiple Myeloma at the 2009 ASCO Annual Meeting 4502 5Proteolix Presents Positive Clinical Data for Carfilzomib in Multiple Myeloma at the 2009 ASCO Annual Meeting 4502 6Keryx Biopharmaceuticals Announces Positive Data from a Randomized Multi Center Placebo Controlled Phase 2 Combination Study of KRX 0401 28Perifos 4500 1Keryx Biopharmaceuticals Announces Positive Data from a Randomized Multi Center Placebo Controlled Phase 2 Combination Study of KRX 0401 28Perifos 4500 2Keryx Biopharmaceuticals Announces Positive Data from a Randomized Multi Center Placebo Controlled Phase 2 Combination Study of KRX 0401 28Perifos 4500 3Keryx Biopharmaceuticals Announces Positive Data from a Randomized Multi Center Placebo Controlled Phase 2 Combination Study of KRX 0401 28Perifos 4500 4Keryx Biopharmaceuticals Announces Positive Data from a Randomized Multi Center Placebo Controlled Phase 2 Combination Study of KRX 0401 28Perifos 4500 5Keryx Biopharmaceuticals Announces Positive Data from a Randomized Multi Center Placebo Controlled Phase 2 Combination Study of KRX 0401 28Perifos 4500 6